Patients Why “rare disease” is a regulatory label, not a patient real... Regulators define a rare disease by how many people have it, and the answer depends on who is counting.
Patients From bedside to breakthroughs: Reimagining the human experie... Patients should be involved in the programme design process from the beginning, as co-creators with full influence over the outcome.
Patients Breaking Bipolar I disorder stigma in the Hispanic community For many Hispanic patients and families, that is where the gap between need and treatment can begin.
Patients Durability and earlier access could reshape diabetic retinop... This year’s World Sight Day turns global attention to the scale of preventable vision loss
Patients Rare diseases, real opportunity: Why the UK’s next challenge... The UK has the science, the talent, and the investment. The next step is ensuring that innovation translates into timely patient impact.
News Aspen, Bambusa close IPOs as Corxel takes SPAC route Aspen Neuroscience and Bambusa Therapeutics get their Nasdaq IPOs over the line, while Corxel eyes a debut via a blank-cheque company merger.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
